Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.
Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study.
Blood 2018 Mar 20. pii: blood-2017-11-816298. doi: 10.1182/blood-2017-11-816298
RNA fusions involving CD28 are rare in peripheral T-Cell lymphomas and concentrate mainly in those derived from follicular helper T cells.
Haematologica 2018 Mar 15. pii: haematol.2017.186767
Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.
Br J Haematol. 2018 May;181(3):341-349. doi: 10.1111/bjh.15184.
Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?
Eur J Nucl Med Mol Imaging. 2018 Apr 12. doi: 10.1007/s00259-018-4005-4.
Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.
J Nucl Med 2018 Apr;59(4):589-595. doi: 10.2967/jnumed.117.193946.
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Blood 2018 Apr 17. pii: blood-2017-11-816405. doi: 10.1182/blood-2017-11-816405.
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
J Clin Oncol. 2018 Apr 19:JCO2017765198. doi: 10.1200/JCO.2017.76.5198
Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma
Blood Adv. 2018 Apr 10;2(7):807-816. doi: 10.1182/bloodadvances.2017015164.
How I manage patients with relapsed/refractory diffuse large B cell lymphoma
Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15412.
Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
Haematologica 2018 May;103(5):840-848. doi: 10.3324/haematol.2017.180554
Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.
Blood. 2018 May 2. pii: blood-2018-02-811174. doi: 10.1182/blood-2018-02-811174.
HLA class I and II diversity contributes to the etiologic heterogeneity of non-Hodgkin lymphoma subtypes
Cancer Res. 2018 May 7. pii: canres.2900.2017. doi: 10.1158/0008-5472.CAN-17-2900.
NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment.
Oncoimmunology. 2017 Dec 20;7(4):e1409322. doi: 10.1080/2162402X.2017.1409322. eCollection 2018.
2018_LYSA_Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from LYSA centers.
Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154.
Progression-Free Survival at 24 Months (PFS24) and Subsequent Outcome For Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled On Randomized Clinical Trials.
Ann. Oncol. 2018 Jun 12. doi: 10.1093/annonc/mdy203.
Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
Br J Haematol. 2018 Aug 16. doi: 10.1111/bjh.15513
An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
Blood. 2018 Aug 1. pii: blood-2018-05-853499. doi: 10.1182/blood-2018-05-853499.
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma
Haematologica 2018 Aug 31. pii: haematol.2018.191429. doi: 10.3324/haematol.2018.191429
How I manage patients with relapsed/refractory diffuse large B cell lymphoma.
Br J Haematol 2018 Sep;182(5):633-643. doi: 10.1111/bjh.15412
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104
Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5
Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1705-1709. doi: 10.1007/s00259-018-4020-5
Lysa
2020_LYSA_Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers
Bone Marrow Transplant. 2020 Jan 17. doi: 10.1038/s41409-020-0783-y
En savoir plus
Lysa
2020_LYSA_A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features
Clin Cancer Res. 2020 Mar 2. doi: 10.1158/1078-0432.CCR-19-3741.
En savoir plus